Posted by Michael Wonder on 19 Mar 2018
Be wary of Canada’s drug price controls and lack of IP protections
19 March 2018 - There is an ill-thought out war underway on brand-name drug prices and pharmaceutical intellectual property. Washington can learn from Canada’s mistakes.
President Trump has asked CEOs of research-based pharmaceutical manufacturers to lower U.S. drug prices and increase jobs in America. Given the fact more is already spent on pharmaceutical R&D in the U.S. than anywhere else, this presents a serious challenge for U.S. and other global pharmaceutical companies.
Differential pricing among country and regional markets have been used in many industries for many years based upon identifying different classes of buyers for which different prices would be used.
